CYTK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cytokinetics Inc (CYTK) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has positive analyst ratings and potential catalysts, the lack of strong proprietary trading signals, insider and hedge fund selling, and mixed financial performance suggest a cautious approach. Holding the stock or waiting for clearer entry signals would be more prudent.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 62.065, and moving averages are converging, suggesting no strong directional trend. The stock is trading near resistance levels (R1: 63.938), with limited upside potential in the short term.
Analysts have raised price targets significantly, with multiple firms maintaining Outperform or Buy ratings.
Upcoming ACACIA-HCM Phase 3 trial results and Myqorzo launch progress are viewed as transformative catalysts.
Positive sentiment around extending aficamten IP to 2041.
Hedge funds and insiders are heavily selling, with hedge fund selling up 5964.05% and insider selling up 561.39%.
Financials show a net loss of -183 million in Q4 2025, albeit with slight YoY improvement.
High implied volatility (129.
suggests elevated risk.
In Q4 2025, revenue increased by 4.89% YoY to $17.76M, but the company remains unprofitable with a net loss of -$183M (up 22% YoY). EPS improved to -1.49 (up 17.32% YoY). Gross margin remains at 100%.
Analysts are bullish, with price targets ranging from $67 to $101. Mizuho, JPMorgan, and RBC Capital highlight significant growth potential, particularly from Myqorzo and the ACACIA-HCM trial. However, UBS and BofA maintain Neutral ratings, citing binary risks and modest near-term updates.
